In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer

Cell Reports

Volumn 16, Issue 1, 2016, Pages 133-147

  Carugo, Alessandro ^a,b   Genovese, Giannicola ^a   Seth, Sahil ^a   Nezi, Luigi ^a   Rose, Johnathon Lynn ^a   Bossi, Daniela ^b   Cicalese, Angelo ^b   Shah, Parantu Krushnakant ^a   Viale, Andrea ^a   Pettazzoni, Piergiorgio Francesco ^a   Akdemir, Kadir Caner ^a   Bristow, Christopher Aaron ^a   Robinson, Frederick Scott ^a   Tepper, James ^a   Sanchez, Nora ^a   Gupta, Sonal ^a   Estecio, Marcos Roberto ^a   Giuliani, Virginia ^a   Dellino, Gaetano Ivan ^b,c   Riva, Laura ^d   Yao, Wantong ^a   Di Francesco, Maria Emilia ^a   Green, Tessa ^a   D'Alesio, Carolina ^b   Corti, Denise ^a   Kang, Ya'an ^a   Jones, Philip ^a   Wang, Huamin ^a   Fleming, Jason Bates ^a   Maitra, Anirban ^a   Pelicci, Pier Giuseppe ^b,c   Chin, Lynda ^a   DePinho, Ronald Anthony ^a   Lanfrancone, Luisa ^b   Heffernan, Timothy Paul ^e   Draetta, Giulio Francesco ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e C4 Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE LYSINE METHYLTRANSFERASE; MYC PROTEIN; UNCLASSIFIED DRUG; WDR5 PROTEIN; MULTIPROTEIN COMPLEX; PROTEIN BINDING; SMALL INTERFERING RNA; WDR5 PROTEIN, HUMAN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA REPLICATION; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; CARCINOGENESIS; CELL PROLIFERATION; DISEASE EXACERBATION; DNA DAMAGE; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; LENTIVIRINAE; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGICAL STRESS; PROTEIN SUBUNIT; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA DAMAGE; EPIGENESIS, GENETIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LENTIVIRUS; MICE; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; PANCREATIC NEOPLASMS; PROTEIN BINDING; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; STRESS, PHYSIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008397717     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.063     Document Type: Article

References (63)

1. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., Perucho, M., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53 (1988), 549–554.
2. American Cancer Society. (2015). Cancer Facts & Figures.
3. Baratta, M.G., Schinzel, A.C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L.C., Kung, A.L., et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 112 (2015), 232–237.
4. Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.C., Muthuswamy, L.B., Johns, A.L., Miller, D.K., Wilson, P.J., Patch, A.M., Wu, J., et al., Australian Pancreatic Cancer Genome Initiative. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 (2012), 399–405.
5. Birmingham, A., Selfors, L.M., Forster, T., Wrobel, D., Kennedy, C.J., Shanks, E., Santoyo-Lopez, J., Dunican, D.J., Long, A., Kelleher, D., et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat. Methods 6 (2009), 569–575.
6. Bonnefoix, T., Callanan, M., Revisiting the concept of phenotypically distinct malignant pancreatic stem-cell subsets based on limiting dilution transplantation assays. J. Clin. Oncol. 28 (2010), e89–e90.
7. Campaner, S., Amati, B., Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div., 7, 2012, 6.
8. Cao, F., Townsend, E.C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53 (2014), 247–261.
9. Chen, X., Xie, W., Gu, P., Cai, Q., Wang, B., Xie, Y., Dong, W., He, W., Zhong, G., Lin, T., Huang, J., Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. Sci. Rep., 5, 2015, 8293.
10. Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364 (2011), 1817–1825.
11. Dang, C.V., c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19 (1999), 1–11.
12. Dawson, M.A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 150 (2012), 12–27.
13. Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D.A., Gu, W., Gautier, J., Dalla-Favera, R., Non-transcriptional control of DNA replication by c-Myc. Nature 448 (2007), 445–451.
14. Gaillard, H., García-Muse, T., Aguilera, A., Replication stress and cancer. Nat. Rev. Cancer 15 (2015), 276–289.
15. Grebien, F., Vedadi, M., Getlik, M., Giambruno, R., Grover, A., Avellino, R., Skucha, A., Vittori, S., Kuznetsova, E., Smil, D., et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat. Chem. Biol. 11 (2015), 571–578.
16. Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003), 437–450.
17. G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
18. Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl. Acad. Sci. USA 111 (2014), 3128–3133.
19. Hu, Y., Smyth, G.K., ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347 (2009), 70–78.
20. Hubert, C.G., Bradley, R.K., Ding, Y., Toledo, C.M., Herman, J., Skutt-Kakaria, K., Girard, E.J., Davison, J., Berndt, J., Corrin, P., et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 27 (2013), 1032–1045.
21. Ischenko, I., Petrenko, O., Hayman, M.J., Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc. Natl. Acad. Sci. USA 111 (2014), 3466–3471.
22. Ishizawa, K., Rasheed, Z.A., Karisch, R., Wang, Q., Kowalski, J., Susky, E., Pereira, K., Karamboulas, C., Moghal, N., Rajeshkumar, N.V., et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7 (2010), 279–282.
23. Kim, J.Y., Banerjee, T., Vinckevicius, A., Luo, Q., Parker, J.B., Baker, M.R., Radhakrishnan, I., Wei, J.J., Barish, G.D., Chakravarti, D., A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol. Cell 54 (2014), 613–625.
24. König, R., Chiang, C.Y., Tu, B.P., Yan, S.F., DeJesus, P.D., Romero, A., Bergauer, T., Orth, A., Krueger, U., Zhou, Y., Chanda, S.K., A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4 (2007), 847–849.
25. Krattenmacher, A., et al. Synthetic lethality screen identifies SMC2 as a new target gene in pancreatic cancer. Pancreatology, 13, 2014, S66.
26. Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol., 10, 2009, R25.
27. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup. The Sequence alignment/map (SAM) format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
28. Liu, H., Takeda, S., Kumar, R., Westergard, T.D., Brown, E.J., Pandita, T.K., Cheng, E.H., Hsieh, J.J., Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467 (2010), 343–346.
29. Meacham, C.E., Ho, E.E., Dubrovsky, E., Gertler, F.B., Hemann, M.T., In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 41 (2009), 1133–1137.
30. Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G., Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006), 1283–1298.
31. Morris, J.P. 4th, Cano, D.A., Sekine, S., Wang, S.C., Hebrok, M., Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120 (2010), 508–520.
32. Murga, M., Campaner, S., Lopez-Contreras, A.J., Toledo, L.I., Soria, R., Montaña, M.F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18 (2011), 1331–1335.
33. Nghiem, P., Park, P.K., Kim, Y., Vaziri, C., Schreiber, S.L., ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. USA 98 (2001), 9092–9097.
34. Omura, N., Goggins, M., Epigenetics and epigenetic alterations in pancreatic cancer. Int. J. Clin. Exp. Pathol. 2 (2009), 310–326.
35. Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476 (2011), 346–350.
36. Possik, P.A., Müller, J., Gerlach, C., Kenski, J.C., Huang, X., Shahrabi, A., Krijgsman, O., Song, J.Y., Smit, M.A., Gerritsen, B., et al. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. Cell Rep. 9 (2014), 1375–1386.
37. Prevo, R., Fokas, E., Reaper, P.M., Charlton, P.A., Pollard, J.R., McKenna, W.G., Muschel, R.J., Brunner, T.B., The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 13 (2012), 1072–1081.
38. Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., Morrison, S.J., Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
39. Sahai, V., Kumar, K., Knab, L.M., Chow, C.R., Raza, S.S., Bentrem, D.J., Ebine, K., Munshi, H.G., BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol. Cancer Ther. 13 (2014), 1907–1917.
40. Schlabach, M.R., Luo, J., Solimini, N.L., Hu, G., Xu, Q., Li, M.Z., Zhao, Z., Smogorzewska, A., Sowa, M.E., Ang, X.L., et al. Cancer proliferation gene discovery through functional genomics. Science 319 (2008), 620–624.
41. Scholl, C., Fröhling, S., Dunn, I.F., Schinzel, A.C., Barbie, D.A., Kim, S.Y., Silver, S.J., Tamayo, P., Wadlow, R.C., Ramaswamy, S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137 (2009), 821–834.
42. Schoppy, D.W., Ragland, R.L., Gilad, O., Shastri, N., Peters, A.A., Murga, M., Fernandez-Capetillo, O., Diehl, J.A., Brown, E.J., Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 122 (2012), 241–252.
43. Schuettengruber, B., Martinez, A.M., Iovino, N., Cavalli, G., Trithorax group proteins: switching genes on and keeping them active. Nat. Rev. Mol. Cell Biol. 12 (2011), 799–814.
44. Sears, R., Leone, G., DeGregori, J., Nevins, J.R., Ras enhances Myc protein stability. Mol. Cell 3 (1999), 169–179.
45. Silva, J.M., Marran, K., Parker, J.S., Silva, J., Golding, M., Schlabach, M.R., Elledge, S.J., Hannon, G.J., Chang, K., Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319 (2008), 617–620.
46. Smith, E., Lin, C., Shilatifard, A., The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25 (2011), 661–672.
47. Stathis, A., Moore, M.J., Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 7 (2010), 163–172.
48. Stellas, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C., Cournia, Z., Tamvakopoulos, C., Klinakis, A., Efstratiadis, A., Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J. Natl. Cancer Inst., 106, 2014, dju320.
49. Steward, M.M., Lee, J.S., O'Donovan, A., Wyatt, M., Bernstein, B.E., Shilatifard, A., Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat. Struct. Mol. Biol. 13 (2006), 852–854.
50. Sun, Y., Bell, J.L., Carter, D., Gherardi, S., Poulos, R.C., Milazzo, G., Wong, J.W., Al-Awar, R., Tee, A.E., Liu, P.Y., et al. WDR5 supports an N-Myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma. Cancer Res. 75 (2015), 5143–5154.
51. Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., Arcaroli, J.J., Messersmith, W.A., Eckhardt, S.G., Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9 (2012), 338–350.
52. Thomas, L.R., Wang, Q., Grieb, B.C., Phan, J., Foshage, A.M., Sun, Q., Olejniczak, E.T., Clark, T., Dey, S., Lorey, S., et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol. Cell 58 (2015), 440–452.
53. Trievel, R.C., Shilatifard, A., WDR5, a complexed protein. Nat. Struct. Mol. Biol. 16 (2009), 678–680.
54. Ventura, A., Meissner, A., Dillon, C.P., McManus, M., Sharp, P.A., Van Parijs, L., Jaenisch, R., Jacks, T., Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA 101 (2004), 10380–10385.
55. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., Jacks, T., Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007), 661–665.
56. Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514 (2014), 628–632.
57. Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, S.A., Ma, W.W., Saleh, M.N., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369 (2013), 1691–1703.
58. Waddell, N., Pajic, M., Patch, A.M., Chang, D.K., Kassahn, K.S., Bailey, P., Johns, A.L., Miller, D., Nones, K., Quek, K., et al., Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 (2015), 495–501.
59. Wang, P., Lin, C., Smith, E.R., Guo, H., Sanderson, B.W., Wu, M., Gogol, M., Alexander, T., Seidel, C., Wiedemann, L.M., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29 (2009), 6074–6085.
60. Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
61. Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., Korsmeyer, S.J., Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378 (1995), 505–508.
62. Zender, L., Xue, W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, J.M., Schirmacher, P., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008), 852–864.
63. Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., Dirks, P.B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 (2009), 806–823.